<Research> CLSA Views CN Biopharma Stock Decline as Attractive Buying Chance, Prefers CSPC PHARMA and SINOPHARM
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Source: aastocks
Market Volatility: China's biotechnology and innovative drug industry is facing volatility due to overvaluation, uncertainty in drug pricing, and delayed business expansions, as reported by CLSA.
Investment Opportunities: Despite the current pullback, CLSA views it as a healthy consolidation, presenting attractive investment opportunities for the upcoming year.
CSPC PHARMA Concerns: CSPC PHARMA's weakened business expansion execution has led to a downgrade in investor confidence, but CLSA believes this may create better buying opportunities.
SINOPHARM Recovery: CLSA anticipates improvements in SINOPHARM's accounts receivable and the support of China's 15th Five-Year Plan to enhance the company's earnings momentum.
Analyst Views on 01093
Wall Street analysts forecast 01093 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01093 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 9.810
Low
Averages
High
Current: 9.810
Low
Averages
High
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
